Compounds > varespladib
Page last updated: 2024-09-04

varespladib and pyrroles

varespladib has been researched along with pyrroles in 3 studies

Compound Research Comparison

Studies
(varespladib)		Trials
(varespladib)		Recent Studies (post-2010)
(varespladib)		Studies
(pyrroles)		Trials
(pyrroles)		Recent Studies (post-2010) (pyrroles)
80114926,1292,81512,100

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Elliott, M; Goulder, M; Hislop, C; Rosenson, RS; Stasiv, Y; Waters, D1
Rosenson, RS1
Bash, D; Brennan, DM; Cavender, MA; Jukema, JW; Kastelein, JJ; Koenig, W; Lincoff, AM; Menon, V; Nambi, V; Nicholls, SJ; Nissen, SE; Rosenson, RS; Schwartz, GG; Wright, RS1

Trials

3 trial(s) available for varespladib and pyrroles

ArticleYear
Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
    Journal of the American College of Cardiology, 2010, Sep-28, Volume: 56, Issue:14

    Topics: Acetates; Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Indoles; Keto Acids; Logistic Models; Male; Middle Aged; Phospholipases A2, Secretory; Prospective Studies; Pyrroles; Reference Values; Treatment Outcome

2010
After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
    Future cardiology, 2011, Volume: 7, Issue:1

    Topics: Acetates; Acute Coronary Syndrome; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Keto Acids; Logistic Models; Male; Middle Aged; Phospholipases A2, Secretory; Pyrroles

2011
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
    JAMA, 2014, Jan-15, Volume: 311, Issue:3

    Topics: Acetates; Acute Coronary Syndrome; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Double-Blind Method; Early Termination of Clinical Trials; Female; Heptanoic Acids; Humans; Indoles; Keto Acids; Male; Middle Aged; Myocardial Infarction; Phospholipases A; Phospholipases A2, Secretory; Pyrroles; Risk; Stroke; Survival Analysis; Treatment Outcome

2014